Novo Nordisk A/S And Sciele Pharma, Inc. Release: PrandiMet(R), First Repaglinide and Metformin HCl Fixed Dose Combination Therapy, Now Available in the United States

PRINCETON, N.J. & ATLANTA--(BUSINESS WIRE)--Novo Nordisk and Sciele Pharma, Inc., a Shionogi Company, today announced the availability of PrandiMet® (repaglinide and metformin HCl) tablets, the first and only fixed-dose combination of the short-acting secretagogue repaglinide (also known as Prandin®) and insulin sensitizer metformin HCl for the treatment of type 2 diabetes in the United States.